Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.

R. Simoni, R. Cavalieri, G. Coppola, L. Ricciotti, O. De Pità, D. Criscuolo, A. Covelli, G. Papa, F. Mandelli

Research output: Contribution to journalArticle

Abstract

This study was designed to evaluate the efficacy and tolerability of recombinant leukocyte interferon alfa-2a (Hoffmann-LaRoche) as single agent in patients with histologically confirmed Mycosis Fungoides. The protocol consisted of a 12 week induction with subcutaneous interferon, escalating from 3 up to 18 million units daily, and a 6 or 9 month maintenance phase for complete or partial responses, respectively, with 18 million units 3 times weekly. 12 patients are evaluable: 5 are in complete remissions, 6 are partial remissions, and one had disease progression. Alfa-2a interferon was well tolerated: only 3 patients had WHO grade IV organ toxicity. Our study documents that recombinant leukocyte alfa 2a is a highly active agent in untreated patients with Mycosis Fungoides. Finally, the dose schedule chosen in this study allows alfa-2a interferon administration on an outpatient basis.

Original languageEnglish
Pages (from-to)93-99
Number of pages7
JournalJournal of Biological Regulators and Homeostatic Agents
Volume1
Issue number2
Publication statusPublished - Apr 1987

Fingerprint

mycosis fungoides
Mycosis Fungoides
interferon-alpha
Interferon-alpha
leukocytes
interferons
remission
Proxy
Interferons
Disease Progression
Appointments and Schedules
Leukocytes
Outpatients
Therapeutics
Maintenance
disease course
interferon alfa-2a
toxicity
dosage

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)

Cite this

Simoni, R., Cavalieri, R., Coppola, G., Ricciotti, L., De Pità, O., Criscuolo, D., ... Mandelli, F. (1987). Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. Journal of Biological Regulators and Homeostatic Agents, 1(2), 93-99.

Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. / Simoni, R.; Cavalieri, R.; Coppola, G.; Ricciotti, L.; De Pità, O.; Criscuolo, D.; Covelli, A.; Papa, G.; Mandelli, F.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 1, No. 2, 04.1987, p. 93-99.

Research output: Contribution to journalArticle

Simoni, R, Cavalieri, R, Coppola, G, Ricciotti, L, De Pità, O, Criscuolo, D, Covelli, A, Papa, G & Mandelli, F 1987, 'Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.', Journal of Biological Regulators and Homeostatic Agents, vol. 1, no. 2, pp. 93-99.
Simoni R, Cavalieri R, Coppola G, Ricciotti L, De Pità O, Criscuolo D et al. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. Journal of Biological Regulators and Homeostatic Agents. 1987 Apr;1(2):93-99.
Simoni, R. ; Cavalieri, R. ; Coppola, G. ; Ricciotti, L. ; De Pità, O. ; Criscuolo, D. ; Covelli, A. ; Papa, G. ; Mandelli, F. / Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. In: Journal of Biological Regulators and Homeostatic Agents. 1987 ; Vol. 1, No. 2. pp. 93-99.
@article{a6d7209e2df84cbb8094d569e9ac59c7,
title = "Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.",
abstract = "This study was designed to evaluate the efficacy and tolerability of recombinant leukocyte interferon alfa-2a (Hoffmann-LaRoche) as single agent in patients with histologically confirmed Mycosis Fungoides. The protocol consisted of a 12 week induction with subcutaneous interferon, escalating from 3 up to 18 million units daily, and a 6 or 9 month maintenance phase for complete or partial responses, respectively, with 18 million units 3 times weekly. 12 patients are evaluable: 5 are in complete remissions, 6 are partial remissions, and one had disease progression. Alfa-2a interferon was well tolerated: only 3 patients had WHO grade IV organ toxicity. Our study documents that recombinant leukocyte alfa 2a is a highly active agent in untreated patients with Mycosis Fungoides. Finally, the dose schedule chosen in this study allows alfa-2a interferon administration on an outpatient basis.",
author = "R. Simoni and R. Cavalieri and G. Coppola and L. Ricciotti and {De Pit{\`a}}, O. and D. Criscuolo and A. Covelli and G. Papa and F. Mandelli",
year = "1987",
month = "4",
language = "English",
volume = "1",
pages = "93--99",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "2",

}

TY - JOUR

T1 - Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.

AU - Simoni, R.

AU - Cavalieri, R.

AU - Coppola, G.

AU - Ricciotti, L.

AU - De Pità, O.

AU - Criscuolo, D.

AU - Covelli, A.

AU - Papa, G.

AU - Mandelli, F.

PY - 1987/4

Y1 - 1987/4

N2 - This study was designed to evaluate the efficacy and tolerability of recombinant leukocyte interferon alfa-2a (Hoffmann-LaRoche) as single agent in patients with histologically confirmed Mycosis Fungoides. The protocol consisted of a 12 week induction with subcutaneous interferon, escalating from 3 up to 18 million units daily, and a 6 or 9 month maintenance phase for complete or partial responses, respectively, with 18 million units 3 times weekly. 12 patients are evaluable: 5 are in complete remissions, 6 are partial remissions, and one had disease progression. Alfa-2a interferon was well tolerated: only 3 patients had WHO grade IV organ toxicity. Our study documents that recombinant leukocyte alfa 2a is a highly active agent in untreated patients with Mycosis Fungoides. Finally, the dose schedule chosen in this study allows alfa-2a interferon administration on an outpatient basis.

AB - This study was designed to evaluate the efficacy and tolerability of recombinant leukocyte interferon alfa-2a (Hoffmann-LaRoche) as single agent in patients with histologically confirmed Mycosis Fungoides. The protocol consisted of a 12 week induction with subcutaneous interferon, escalating from 3 up to 18 million units daily, and a 6 or 9 month maintenance phase for complete or partial responses, respectively, with 18 million units 3 times weekly. 12 patients are evaluable: 5 are in complete remissions, 6 are partial remissions, and one had disease progression. Alfa-2a interferon was well tolerated: only 3 patients had WHO grade IV organ toxicity. Our study documents that recombinant leukocyte alfa 2a is a highly active agent in untreated patients with Mycosis Fungoides. Finally, the dose schedule chosen in this study allows alfa-2a interferon administration on an outpatient basis.

UR - http://www.scopus.com/inward/record.url?scp=0023323406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023323406&partnerID=8YFLogxK

M3 - Article

C2 - 3504088

AN - SCOPUS:0023323406

VL - 1

SP - 93

EP - 99

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -